Please login to the form below

Not currently logged in
Email:
Password:

durvalumab

This page shows the latest durvalumab news and features for those working in and with pharma, biotech and healthcare.

Roche gets FDA nod for Tecentriq in small cell lung cancer

Roche gets FDA nod for Tecentriq in small cell lung cancer

Meanwhile, AstraZeneca is also testing its PD-L1 inhibitor Imfinzi (durvalumab) in first-line ES-SCLC as a monotherapy and in combination with its investigational CTLA4 inhibitor tremelimumab on top of

Latest news

More from news
Approximately 10 fully matching, plus 73 partially matching documents found.

Latest Intelligence

  • AstraZeneca’s oncology renaissance AstraZeneca’s oncology renaissance

    olaparib) plus biologic PD-L1 immunotherapy Imfinzi (durvalumab).

  • Cancer immunotherapy: What's on the horizon? Cancer immunotherapy: What's on the horizon?

    And AZ’s Imfinzi (durvalumab) meanwhile has shown its worth as a maintenance therapy to stop recurrence of earlier-stage, locally-advanced NSCLC.

  • Pharma deals in August 2015 Pharma deals in August 2015

    AstraZeneca will collaborate with Peregrine on a non-exclusive basis looking at the combination of bavituximab and durvalumab [MEDI4736] in solid tumours. ... No financial terms were disclosed but Mirati will conduct and fund the initial phase I/II

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Random42 Scientific Communication

Random42 is the world's leading medical animation company. Over the past 25 years we have produced core digital assets for...

Latest intelligence

50 questions for delivering an exceptional healthcare brand experience
Our 50-question brand planning checklist for healthcare ensures you deliver an exceptional experience, based on what your stakeholders want and need...
The brand strategy revolution
Introducing a new tool for developing a stakeholder-centric brand, based on the experience your patients and their HCPs want and need....
How Medisafe is using AI to improve patient adherence
Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....

Infographics